• About
    • Leadership
      • Management Team
      • Board of Directors
    • Partners
      • Research Partners
      • Strategic Investors
    • Scientific Advisors
      • Founders
      • Advisory Board
    • Careers
      • Open Positions
  • Science
    • Redefining Disease
      • Precision Medicine
      • Genetically-Defined AMD
      • Expanded Access
    • Understanding Ocular Disease
      • CLARITY Studies
    • Therapeutic Modalities
      • Therapeutic Approach
      • Recombinant Proteins
      • Gene Therapy
      • Monoclonal Antibodies
  • Pipeline
    • Programs
      • Complement Factor H
  • Investors & Media
    • News
    • Events & Presentations
    • Stock Information
    • Financials
    • Governance
    • Resources
  • Contact
Gemini Therapeutics Logo
  • About
    • Leadership
      • Management Team
      • Board of Directors
    • Partners
      • Research Partners
      • Strategic Investors
    • Scientific Advisors
      • Founders
      • Advisory Board
    • Careers
      • Open Positions
  • Science
    • Redefining Disease
      • Precision Medicine
      • Genetically-Defined AMD
      • Expanded Access
    • Understanding Ocular Disease
      • CLARITY Studies
    • Therapeutic Modalities
      • Therapeutic Approach
      • Recombinant Proteins
      • Gene Therapy
      • Monoclonal Antibodies
  • Pipeline
    • Programs
      • Complement Factor H
  • Investors & Media
    • News
    • Events & Presentations
    • Stock Information
    • Financials
    • Governance
    • Resources
  • Contact
Home Contact

Contact

Gemini Therapeutics
300 One Kendall Square, 3rd Floor
Cambridge, MA 02139

General Inquiries

info@geminitherapeutics.com

Investors and Media

Argot Partners
gemini@argotpartners.com
212.600.1902

Business Development

bizdev@geminitherapeutics.com

Gemini Therapeutics Logo
  • Contact
  • Privacy Policy
  • Follow:
© 2021 Gemini Therapeutics